Search hospitals > Iowa > Davenport

Genesis Cancer Care Institute

Claim this profile
Davenport, Iowa 52804
Global Leader in Breast Cancer
Global Leader in Breast cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for HER2 Negative
42 reported clinical trials
1 medical researcher
Photo of Genesis Cancer Care Institute in DavenportPhoto of Genesis Cancer Care Institute in Davenport

Summary

Genesis Cancer Care Institute is a medical facility located in Davenport, Iowa. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer, HER2 Negative and other specialties. Genesis Cancer Care Institute is involved with conducting 42 clinical trials across 48 conditions. There are 1 research doctors associated with this hospital, such as David M. Spector.

Area of expertise

1Breast Cancer
Global Leader
Genesis Cancer Care Institute has run 14 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
ER negative
2Breast Cancer
Global Leader
Genesis Cancer Care Institute has run 12 trials for Breast cancer. Some of their research focus areas include:
HER2 positive
ER negative
PR negative

Top PIs

Clinical Trials running at Genesis Cancer Care Institute

Lung Cancer
Non-Small Cell Lung Cancer
ALK Gene Rearrangement
Cancer
Anaplastic Large Cell Lymphoma
Squamous Cell Carcinoma
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Genesis Cancer Care Institute?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security